WO2015050957A3 - Treatments for systemic lupus erythematosus - Google Patents

Treatments for systemic lupus erythematosus Download PDF

Info

Publication number
WO2015050957A3
WO2015050957A3 PCT/US2014/058576 US2014058576W WO2015050957A3 WO 2015050957 A3 WO2015050957 A3 WO 2015050957A3 US 2014058576 W US2014058576 W US 2014058576W WO 2015050957 A3 WO2015050957 A3 WO 2015050957A3
Authority
WO
WIPO (PCT)
Prior art keywords
lupus erythematosus
systemic lupus
treatments
elf4
bankl
Prior art date
Application number
PCT/US2014/058576
Other languages
French (fr)
Other versions
WO2015050957A8 (en
WO2015050957A2 (en
Inventor
Marta E. ALARCON RIQUELME
Ying Yu
Ramesh Kumar
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of WO2015050957A2 publication Critical patent/WO2015050957A2/en
Publication of WO2015050957A8 publication Critical patent/WO2015050957A8/en
Publication of WO2015050957A3 publication Critical patent/WO2015050957A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]

Abstract

The disclosure involves the identification of the Eukaryotic initiation factor 4 (elF4) machinery as a downstream effector of the B-cell scaffold protein with ankyrin repeats 1 (Bankl )-mediated regulation of IL-6 expression. Thus, methods for treating patients suffering from autoimmune diseases such as systemic lupus erythematosus by targeting elF4 function are provided.
PCT/US2014/058576 2013-10-02 2014-10-01 Treatments for systemic lupus erythematosus WO2015050957A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361885859P 2013-10-02 2013-10-02
US61/885,859 2013-10-02

Publications (3)

Publication Number Publication Date
WO2015050957A2 WO2015050957A2 (en) 2015-04-09
WO2015050957A8 WO2015050957A8 (en) 2015-09-11
WO2015050957A3 true WO2015050957A3 (en) 2015-11-12

Family

ID=52779279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/058576 WO2015050957A2 (en) 2013-10-02 2014-10-01 Treatments for systemic lupus erythematosus

Country Status (1)

Country Link
WO (1) WO2015050957A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874561T3 (en) 2014-09-17 2021-11-05 Celgene Car Llc MK2 inhibitors and their uses
CN105902533B (en) * 2016-05-23 2018-04-20 浙江省医学科学院 Purposes of the compound cercosporamide in immunopotentiator is prepared
US11602524B2 (en) 2019-12-02 2023-03-14 New York University Selective inhibition of T Follicular Helper cells for treatment of autoimmune disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148462A1 (en) * 2005-10-13 2009-06-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US20130209543A1 (en) * 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
US20130209578A1 (en) * 2010-08-11 2013-08-15 Universite De Montreal Combinatory Cancer Treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148462A1 (en) * 2005-10-13 2009-06-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US20130209578A1 (en) * 2010-08-11 2013-08-15 Universite De Montreal Combinatory Cancer Treatment
US20130209543A1 (en) * 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GROLLEAU ET AL.: "Impaired translational response and increased protein kinase PKR expression in T cells from lupus patients.", J CLIN INVEST., vol. 106, no. 12, 2000, pages 1561 - 1568, XP055235484 *
LOPEZ-PELAEZ ET AL.: "Cot/tpl2-MKK1/2-Erk1/2 controls mTORC1-mediated mRNA translation in Toll-like receptor-activated macrophages", MOL BIOL CELL ., vol. 23, no. 15, August 2012 (2012-08-01), pages 2982 - 2992, XP055235483 *
WU ET AL.: "BANK1 controls CpG-induced IL -6 secretion via a p38 and MNK1/2/eIF4E translation initiation pathway.", J IMMUNOL., vol. 191, no. 12, December 2013 (2013-12-01), pages 6110 - 6, XP055235488, DOI: doi:10.4049/jimmunol.1301203 *

Also Published As

Publication number Publication date
WO2015050957A8 (en) 2015-09-11
WO2015050957A2 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
MX2023008686A (en) Modulatory polynucleotides.
WO2016011306A3 (en) Terminal modifications of polynucleotides
EP3538548A4 (en) Il-2 variants for the treatment of autoimmune diseases
EP3469522A4 (en) Accelerator for deep neural networks
EP3465550A4 (en) Accelerator for deep neural networks
MX2018014154A (en) Modulatory polynucleotides.
WO2016011222A3 (en) Circular polynucleotides
EP3229734A4 (en) Accommodative, curvature-changing intraocular lenses
MX2021008663A (en) Improved il-6 antibodies.
EP3522332A4 (en) Charger
EP3665544A4 (en) Database engine
EP3378442A4 (en) Improved accommodative intraocular lens
EP3331345A4 (en) Hedge trimmer
ZA201608079B (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
EP3433563A4 (en) Holster
EP3629910A4 (en) Seizure onset zone localization
EP3313927A4 (en) Dilithium initiators
EP3455350A4 (en) Combination prime: boost therapy
WO2015050957A3 (en) Treatments for systemic lupus erythematosus
WO2017035319A8 (en) Methods for treatment of polycystic kidney disease
EP3432821A4 (en) Surgical platform supported by multiple arms
WO2017103280A9 (en) Intravesical therapy for bladder cancer
EP3525570A4 (en) Line trimmer
WO2016086022A3 (en) Heteroaromatic imidazolyl compounds and methods for treating cancer
WO2016081701A3 (en) CDDO-Me AS A THERAPY FOR LUPUS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14850884

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14850884

Country of ref document: EP

Kind code of ref document: A2